TY - JOUR
T1 - Outcomes following transcatheter repair in patients with functional mitral regurgitation not receiving guideline directed medical therapy in Israel
AU - Leibowitz, David
AU - Haberman, Dan
AU - Goland, Sorel
AU - George, Jacob
AU - Beeri, Ronen
AU - Planer, David
AU - Wolf, Rafael
AU - Kutsher, Becky
AU - Hasin, Tal
AU - Shuvy, Mony
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/6/16
Y1 - 2023/6/16
N2 - Background: Transcatheter edge to edge repair (TEER) improves prognosis in patients with functional mitral regurgitation (FMR) receiving guideline directed medical therapy (GDMT). Many patients with FMR do not receive GDMT and the utility of TEER in this population remains unclear. Methods: We retrospectively studied patients undergoing TEER. Clinical, echocardiographic and procedural variables were recorded. GDMT was defined as use of RAAS inhibitors and MRAs unless GFR was under 30 as well as beta blockers. The primary endpoint of the study was one year mortality. Results: 168 patients (mean age 71.3 ± 9.3; 66% males) with FMR who underwent TEER were included of whom 116 (69%) received GDMT at the time of TEER and 52 (31%) did not. There were no significant demographic or clinical differences between the groups. There were no significant differences in procedural success and complications between groups. One year mortality was identical in the two groups (15% vs. 15%; RR 1.06, CI 0.43–2.63, P = 0.90). Conclusions: Our findings suggest that procedural success and one year mortality following TEER was not significantly different in HFREF patients with FMR with or without GDMT. Larger, prospective studies are necessary to define the benefit of TEER in this population.
AB - Background: Transcatheter edge to edge repair (TEER) improves prognosis in patients with functional mitral regurgitation (FMR) receiving guideline directed medical therapy (GDMT). Many patients with FMR do not receive GDMT and the utility of TEER in this population remains unclear. Methods: We retrospectively studied patients undergoing TEER. Clinical, echocardiographic and procedural variables were recorded. GDMT was defined as use of RAAS inhibitors and MRAs unless GFR was under 30 as well as beta blockers. The primary endpoint of the study was one year mortality. Results: 168 patients (mean age 71.3 ± 9.3; 66% males) with FMR who underwent TEER were included of whom 116 (69%) received GDMT at the time of TEER and 52 (31%) did not. There were no significant demographic or clinical differences between the groups. There were no significant differences in procedural success and complications between groups. One year mortality was identical in the two groups (15% vs. 15%; RR 1.06, CI 0.43–2.63, P = 0.90). Conclusions: Our findings suggest that procedural success and one year mortality following TEER was not significantly different in HFREF patients with FMR with or without GDMT. Larger, prospective studies are necessary to define the benefit of TEER in this population.
KW - Congestive heart failure
KW - Mitral regurgitation
KW - Transcatheter repair
UR - http://www.scopus.com/inward/record.url?scp=85161971910&partnerID=8YFLogxK
U2 - 10.1186/s12872-023-03344-2
DO - 10.1186/s12872-023-03344-2
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 37328829
AN - SCOPUS:85161971910
SN - 1471-2261
VL - 23
JO - BMC Cardiovascular Disorders
JF - BMC Cardiovascular Disorders
IS - 1
M1 - 304
ER -